Last reviewed · How we verify

innohep® — Competitive Intelligence Brief

innohep® (innohep®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Low-molecular-weight heparin (LMWH). Area: Cardiovascular.

marketed Low-molecular-weight heparin (LMWH) Antithrombin III (enhancer); Factor Xa and Thrombin (indirect targets) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

innohep® (innohep®) — LEO Pharma. Innohep is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
innohep® TARGET innohep® LEO Pharma marketed Low-molecular-weight heparin (LMWH) Antithrombin III (enhancer); Factor Xa and Thrombin (indirect targets)
Low dose nadroparin Low dose nadroparin Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) marketed Low-molecular-weight heparin (LMWH) Factor Xa, Thrombin (Factor IIa)
Intermediate dose dalteparin Intermediate dose dalteparin Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) marketed Low-molecular-weight heparin (LMWH) Antithrombin III (indirect); Factor Xa and Thrombin (downstream targets)
normal injection of Enoxaparine normal injection of Enoxaparine French Cardiology Society marketed Low-molecular-weight heparin (LMWH) Factor Xa and Factor IIa (via antithrombin III enhancement)
Hepalean Heparin Hepalean Heparin McMaster University marketed Low-molecular-weight heparin (LMWH) Antithrombin III (indirect target); Factors Xa and IIa
Intermediate dose nadroparin Intermediate dose nadroparin Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) marketed Low-molecular-weight heparin (LMWH) Factor Xa, Thrombin (via antithrombin III enhancement)
Intermediate dose enoxaparin Intermediate dose enoxaparin Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) marketed Low-molecular-weight heparin (LMWH) Coagulation factors Xa and IIa (via antithrombin III)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Low-molecular-weight heparin (LMWH) class)

  1. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 7 drugs in this class
  2. University of Melbourne · 3 drugs in this class
  3. French Cardiology Society · 2 drugs in this class
  4. Ottawa Hospital Research Institute · 2 drugs in this class
  5. McMaster University · 2 drugs in this class
  6. Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
  7. GlaxoSmithKline · 1 drug in this class
  8. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
  9. Cristália Produtos Químicos Farmacêuticos Ltda. · 1 drug in this class
  10. Helsinki University Central Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). innohep® — Competitive Intelligence Brief. https://druglandscape.com/ci/innohep. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: